Coram LLC
Industry
- Biotechnology
See more in Biomedtracker
Latest on Coram LLC
In Vivo
Device Transactions Thirty-six financings brought in $1.2 billion during 2013’s fourth quarter, almost double Q3’s $644 million total, making it the most lucrative quarter of 2013. The majority (63%)
In Vivo
Exhibit 1 Top Alliances In November 2013 (Potential Deal Value In $M*) *Potential deal value is the sum of up-front fees plus pre-commercialization money. Strategic Transactions Exhibit 2 Top Mergers
In Vivo
IN VITRO DIAGNOSTICS Alliances Almac Group Ltd. Almac Diagnostics Genomic Health Inc. Genomic Health Inc. licensed rights to fellow cancer testing company Almac Diagnostics ’ technology and IP